The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Epic Sciences
Analyses circulating tumor cells to provide actionable data for personalized cancer therapies.
What they do
Epic Sciences develops highly sensitive cancer diagnostics that detect and characterize circulating tumor cells in blood samples. Pharmaceutical firms and laboratory oncologists purchase its platform to monitor metastatic cancer progression, detect disease recurrence, and optimize therapy selection.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- San Diego, United States
- Region
- North America
- Founded
- 2008
- Total funding
- $200M raised
Notable investors: Deerfield Management, Blue Shield of California, Domain Associates, Section 32.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA